By Business/Source
Currency:USD
2024/FY
Stock NameRevenueRatio
Developing novel therapeutics to treat immuno-inflammatory disorders with high unmet medical need41.1M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States41.1M100.00%